GLOSSARY · PLAIN DEFINITIONS
CDMO terms: drug substance, capacity, and qualification
Plain-language definitions for early biologics manufacturing screens. Source announcement and retrieval dates appear centrally on Sources & dates.
- CDMO (Contract Development and Manufacturing Organization)
- A third-party company hired by a biopharma sponsor to develop manufacturing processes, run analytical testing, and produce clinical or commercial drug material under cGMP rules.
- Drug substance (DS) vs. drug product (DP)
- Drug substance is the unformulated active biologic molecule produced in upstream and downstream manufacturing runs. Drug product is the finished dosage form filled into vials or syringes for patient use.
- Mammalian expression
- Using mammalian host cell lines to express complex therapeutic proteins such as monoclonal antibodies. See Protein scope for reviewed site wording.
- Disclosed site capacity vs. bookable capacity
- Disclosed capacity is the nominal size or total of installed bioreactors (in L or kL) published by a vendor. Bookable capacity is open suite schedule available for a new sponsor campaign. How to read capacity figures.
- Single-use vs. stainless steel bioreactors
- Single-use bioreactors run cell culture inside disposable sterile polymer bags, whereas stainless steel bioreactors use fixed clean-in-place steel vessels. Reviewed sites publish capacities in their own native scales and configurations; see Capacity.
- Bioconjugate / ADC (Antibody-Drug Conjugate)
- A targeted biologic linking an antibody to a payload/linker component, involving conjugation manufacturing steps distinct from standalone unconjugated antibody drug substance.